MX2022004194A - Anticuerpos contra el receptor de virus de la polio (pvr) y usos de los mismos. - Google Patents
Anticuerpos contra el receptor de virus de la polio (pvr) y usos de los mismos.Info
- Publication number
- MX2022004194A MX2022004194A MX2022004194A MX2022004194A MX2022004194A MX 2022004194 A MX2022004194 A MX 2022004194A MX 2022004194 A MX2022004194 A MX 2022004194A MX 2022004194 A MX2022004194 A MX 2022004194A MX 2022004194 A MX2022004194 A MX 2022004194A
- Authority
- MX
- Mexico
- Prior art keywords
- pvr
- antibodies against
- polio virus
- virus receptor
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
- C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Reproductive Health (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962912534P | 2019-10-08 | 2019-10-08 | |
| PCT/IL2020/051082 WO2021070181A1 (en) | 2019-10-08 | 2020-10-07 | Antibodies against the poliovirus receptor (pvr) and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022004194A true MX2022004194A (es) | 2022-05-02 |
Family
ID=73038283
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022004194A MX2022004194A (es) | 2019-10-08 | 2020-10-07 | Anticuerpos contra el receptor de virus de la polio (pvr) y usos de los mismos. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220372161A1 (enExample) |
| EP (1) | EP4041392A1 (enExample) |
| JP (2) | JP7754506B2 (enExample) |
| KR (1) | KR20220082007A (enExample) |
| CN (2) | CN114502595B (enExample) |
| AU (1) | AU2020363041B2 (enExample) |
| BR (1) | BR112022006620A2 (enExample) |
| CA (1) | CA3156983A1 (enExample) |
| IL (1) | IL291540A (enExample) |
| MX (1) | MX2022004194A (enExample) |
| WO (1) | WO2021070181A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2024011278A (es) | 2022-03-15 | 2024-09-25 | Compugen Ltd | Anticuerpos antagonistas de il-18bp y su uso en monoterapia y terapia de combinacion en el tratamiento del cancer. |
| KR102615797B1 (ko) * | 2022-04-28 | 2023-12-19 | 가톨릭대학교 산학협력단 | T 세포에 의한 교모세포종 치료 효과의 유효성 예측 방법 |
| AU2023331612A1 (en) | 2022-09-04 | 2025-02-13 | Nectin Therapeutics Ltd. | Drug conjugates of humanized anti pvr antibodies |
| TW202515608A (zh) | 2023-06-26 | 2025-04-16 | 以色列商坎布根有限公司 | Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| DE122004000008I1 (de) | 1991-06-14 | 2005-06-09 | Genentech Inc | Humanisierter Heregulin Antikörper. |
| EP0714409A1 (en) | 1993-06-16 | 1996-06-05 | Celltech Therapeutics Limited | Antibodies |
| KR101155191B1 (ko) | 1999-01-15 | 2012-06-13 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| EP1481993A1 (en) * | 2003-05-28 | 2004-12-01 | Xerion Pharmaceuticals AG | Modulation of the poliovirus receptor function |
| JP6296650B2 (ja) | 2013-03-13 | 2018-03-20 | 国立大学法人 筑波大学 | 免疫疾患に対する医薬組成物 |
| SG10202006538TA (en) * | 2014-12-23 | 2020-08-28 | Bristol Myers Squibb Co | Antibodies to tigit |
| JP5995117B2 (ja) | 2015-01-26 | 2016-09-21 | 国立大学法人 筑波大学 | 可溶型ｃｄ１５５タンパク質を用いた癌の検出方法 |
| CA2998589A1 (en) | 2015-09-14 | 2017-03-23 | Compass Therapeutics Llc | Compositions and methods for treating cancer via antagonism of the cd155/tigit pathway and tgf-.beta. |
| IL296874A (en) * | 2016-03-01 | 2022-11-01 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Antibodies specific for the human poliovirus receptor |
-
2020
- 2020-10-07 EP EP20799841.0A patent/EP4041392A1/en active Pending
- 2020-10-07 US US17/764,373 patent/US20220372161A1/en active Pending
- 2020-10-07 MX MX2022004194A patent/MX2022004194A/es unknown
- 2020-10-07 WO PCT/IL2020/051082 patent/WO2021070181A1/en not_active Ceased
- 2020-10-07 AU AU2020363041A patent/AU2020363041B2/en active Active
- 2020-10-07 CA CA3156983A patent/CA3156983A1/en active Pending
- 2020-10-07 CN CN202080071097.9A patent/CN114502595B/zh active Active
- 2020-10-07 JP JP2022518775A patent/JP7754506B2/ja active Active
- 2020-10-07 BR BR112022006620A patent/BR112022006620A2/pt unknown
- 2020-10-07 CN CN202510568361.4A patent/CN120424218A/zh active Pending
- 2020-10-07 KR KR1020227014889A patent/KR20220082007A/ko active Pending
-
2022
- 2022-03-21 IL IL291540A patent/IL291540A/en unknown
-
2025
- 2025-04-21 JP JP2025069830A patent/JP2025118688A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112022006620A2 (pt) | 2022-08-30 |
| KR20220082007A (ko) | 2022-06-16 |
| EP4041392A1 (en) | 2022-08-17 |
| JP2022553129A (ja) | 2022-12-22 |
| AU2020363041B2 (en) | 2025-11-06 |
| WO2021070181A1 (en) | 2021-04-15 |
| CN114502595A (zh) | 2022-05-13 |
| US20220372161A1 (en) | 2022-11-24 |
| CA3156983A1 (en) | 2021-04-15 |
| IL291540A (en) | 2022-05-01 |
| CN114502595B (zh) | 2025-05-23 |
| JP7754506B2 (ja) | 2025-10-15 |
| CN120424218A (zh) | 2025-08-05 |
| AU2020363041A1 (en) | 2022-04-14 |
| JP2025118688A (ja) | 2025-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022004194A (es) | Anticuerpos contra el receptor de virus de la polio (pvr) y usos de los mismos. | |
| CL2020003096A1 (es) | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación | |
| CY1124771T1 (el) | Αντισωματα εναντι-σορτιλiνης και μεθοδοι χρησης αυτων | |
| EA202091130A1 (ru) | Лиофилизованный препарат моноклонального антитела к транстиретину | |
| CO2022002573A2 (es) | Anticuerpos contra ilt2 y uso de los mismos | |
| ECSP18005520A (es) | Anticuerpos de factor xi y métodos de uso | |
| EA201991005A1 (ru) | Антитела и полипептиды, направленные против cd127 | |
| MX2017002230A (es) | Anticuerpos anti-lag3 y fragmentos de union a antigeno. | |
| CL2021000258A1 (es) | Anticuerpos anti-btn3a y su uso en el tratamiento del cáncer o trastornos infecciosos. | |
| UY36942A (es) | Proteínas de unión a antígeno que activan el receptor de leptina | |
| PE20200486A1 (es) | Anticuerpos anti-cd33 y metodos para utilizarlos | |
| BR112018067522A2 (pt) | anticorpos específicos para receptor de poliovírus humano (pvr) | |
| EA202190138A1 (ru) | Анти-sirp-бета1 антитела и способы их использования | |
| EA201790339A1 (ru) | Комбинированные препараты с антителами к cd40 | |
| BR112020015498A8 (pt) | Anticorpos anti-pd-1 | |
| CO2023002375A2 (es) | Anticuerpos contra ilt2 y uso de los mismos | |
| CL2021000146A1 (es) | Anticuerpos humanizados contra psma | |
| EA202090791A1 (ru) | Агонистические антитела против cd40 | |
| EA202190647A1 (ru) | Антитела к klrg1 | |
| EA202190183A1 (ru) | Антитела к siglec-5 и способы их применения | |
| CL2021001607A1 (es) | Anticuerpos anti-pmel17 y conjugados de los mismos | |
| EA202092085A1 (ru) | ТЕРАПЕВТИЧЕСКИЕ АНТИТЕЛА ПРОТИВ sPLA2-GIB И ИХ ПРИМЕНЕНИЕ | |
| UY37598A (es) | Anticuerpos miméticos de fgf21 y usos de los mismos | |
| EA201992522A1 (ru) | КОМБИНАЦИЯ БИСПЕЦИФИЧЕСКОГО АНТИТЕЛА К ErbB-2/ErbB-3 С ЭНДОКРИННОЙ ТЕРАПИЕЙ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ | |
| EA201892244A1 (ru) | МОНОВАЛЕНТНЫЙ ИНГИБИТОР ВЗАИМОДЕЙСТВИЯ huTNFR1 |